Carisma Therapeutics stock plunges after Nasdaq delisting notice
NegativeFinancial Markets

Carisma Therapeutics is facing a significant setback as its stock price has plummeted following a delisting notice from Nasdaq. This development is crucial as it raises concerns about the company's future and investor confidence. The delisting could limit the company's access to capital and hinder its growth prospects, making it a situation worth monitoring closely.
— Curated by the World Pulse Now AI Editorial System